Form 4: Seres Therapeutics Director Dere Willard H. Reports Stock Option Grant

Director Dere Willard H. reports the acquisition of stock options in Seres Therapeutics, Inc.

Summary

• On April 10, 2025, Dere Willard H., a director of Seres Therapeutics, Inc., was granted stock options to purchase 100,000 shares of common stock.
• The exercise price of the stock options is $0.58 per share.
• The options vest fully on the earlier of April 10, 2026, or the day before the company's 2026 annual meeting of shareholders.
• The options expire on April 9, 2035.
• Following the transaction, Dere Willard H. directly owns derivative securities for 100,000 shares.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing related to stock option grants, which is generally neutral. The grant itself can be seen as a positive sign of aligning director interests with shareholders, but it's not a major event.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of one year is fairly typical, as is the ten-year option term.

Stakeholder Impact

• The stock option grant could have a minor positive impact on shareholder sentiment as it aligns the director's interests with those of the shareholders.

Key Dates

Keywords

stock options, Form 4, Seres Therapeutics, MCRB, director, beneficial ownership, Derivatives